| Filed On | Filing |
|---|---|
| 12 Nov 2026 | EFFECT |
| 12 Nov 2026 | 424B5 |
| 09 Nov 2026 | SCHEDULE 13D/A |
| 05 Nov 2026 | S-3 |
| 05 Nov 2026 | 424B5 |
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Fate Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN |
| 04 Nov 2026 |
Form 4: Adawi Kamal, Chief Financial Officer
Sold 6,582 shares ($13.5K) |
| 03 Nov 2026 | 144 |
| 28 Sep 2026 |
8-K: Other Events
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN |
| 13 Aug 2026 | S-8 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge |
| 05 Aug 2026 |
Form 4: Tahl Cindy, See Remarks
Sold 38,800 shares ($95.4K) |
| 05 Aug 2026 |
Form 4: Valamehr Bahram, Director
Sold 43,947 shares ($108K) |
| 04 Aug 2026 | 144 |
| 04 Aug 2026 | 144 |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 15 Jun 2026 |
Form 4: Redmile Group, Llc, Director and 1 other
Granted 87,900 Stock Option (Right to Buy) |
Loading...